Chandra Bhagat Pharma Ltd

Chandra Bhagat Pharma Ltd. announced the approval of its audited financial results for the year ended March 31, 2026, during a board meeting held on May 25, 2026. The audit report, furnished by the statutory auditor, presented an unmodified opinion on the annual financial results. The trading window for company shares will open 48 hours after the announcement of the financial statement.

Chandra Bhagat Pharma Ltd's Board of Directors approved the audited financial results for the year ended March 31, 2026, during their meeting held on May 25, 2026. The audit report, furnished by the statutory auditor, had an unmodified opinion. The trading window for the company's shares will open 48 hours after the announcement of the financial statement.

Chandra Bhagat Pharma Ltd has announced a meeting of its Board of Directors scheduled for May 25, 2026, to consider and approve the audited financial results for the half year and year ended March 31, 2026. The meeting will be held at the company's registered office in Mumbai.

Chandra Bhagat Pharma Limited has announced its decision to expand its international presence by opening a new office in Dubai, United Arab Emirates. The new office, which is expected to commence operations by 31st March 2026, will serve as an International Business/Representative Office. The objective of this initiative is to expand the company's global footprint, enhance export opportunities, and strengthen relationships with international clients and partners. This move aligns with the company's strategic growth plans to tap international markets and enhance its global business operations.

Chandra Bhagat Pharma Ltd has announced the closure of the trading window for all directors, officers, and KMP (key managerial personal) in accordance with the company's code of Internal Procedure and Conduct of Regulating, Monitoring and Reporting of Trading by Employee and other connected person. The closure is pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading ) Regulation, 2015 and BSE Circular Ref. No. List/COMP//01/2019-20 dated 2nd April, 2019. The trading window will remain closed with immediate effect and will open 48 hours after the announcement of Financial result for the half year and year ended 31st March, 2026.

Chandra Bhagat Pharma Ltd. announced the outcome of its Board Meeting held on 13th November, 2025. The Board approved the Un-Audited Financial Result for the half year ended on 30th September, 2025. The review report was provided by the Statutory Auditor in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015. The 'Trading Window' for trading in the shares of the Company will open after 48 hours from the Announcement of Financial Statement for the Directors and Key Managerial Personnel/Designated Employees/ Connected person of the Company as defined in the code of conduct for prohibition of Insider Trading of the Company.

Chandra Bhagat Pharma Ltd. announced the outcome of their Board Meeting held on 13th November, 2025. The Board approved the Un-Audited Financial Result of the Company for the half year ended on 30th September, 2025. The 'Trading Window' for trading in the shares of the Company will open after 48 hours from the Announcement of Financial Statement for the Directors and Key Managerial Personnel/Designated Employees/ Connected person of the Company as defined in the code of conduct for prohibition of Insider Trading of the Company. The Limited Review Report was furnished by the Statutory Auditor of the Company in compliance with Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015.

Chandra Bhagat Pharma Ltd has announced that a meeting of the Board of Directors will be held on November 13, 2025, at 05:00 PM at the Registered Office of the Company. The meeting will consider the Un-audited Financial Statement of the Company for the half year ended 30th September, 2025, along with other businesses.

Chandra Bhagat Pharma Ltd, a company with paid-up equity share capital not exceeding rupees ten crore and net worth not exceeding rupees twenty-five crore, as on the last day of previous financial year, and listed on the SME Exchange, is exempted from submitting the Corporate Governance Report for the quarter ended 30th September, 2025. This exemption is in accordance with Regulation 15 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, and applies to the company due to its status and the regulations for listed entities on the SME Exchange.

Chandra Bhagat Pharma Ltd has announced the closure of the trading window for all directors, officers, key managerial personnel (KMP), and designated employees. The closure is in accordance with the company's code of internal procedure and conduct, and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015. The trading window will remain closed until 48 hours after the announcement of the financial result for the half year ending on 30th September, 2025. All KMPs and designated employees have been notified about the closure.